A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Inclusion Criteria:

United States of America (USA) specific inclusion criterion:

• Participant must be 12 to <18 years of age at the time of signing the Informedconsent/assent according to local regulation

Rest of world (ROW) specific inclusion criterion:

• Participant must be 2 to <18 years of age at the time of signing the Informedconsent/assent according to local regulation

Global inclusion criteria:

• Participant has a diagnosis of generalized myasthenia gravis (gMG) confirmed by aprior positive serologic test result to acetylcholine receptor (AChR) prior toScreening

• Participant meets the criteria as defined by the Myasthenia Gravis Foundation ofAmerica (MGFA) Clinical Classification II to IV at Screening

• Participants with gMG, including:

• An MG-activities of daily living (MG-ADL) total score of 6 or more in adolescentsfrom 12 years to <18 years of age at Screening

• Documented weakness in at least 1 limb, neck, or bulbar muscle in children from 2years to <12 years of age at Screening (does not apply to US)

• Documented vaccination against meningococcal infections within 3 years prior tostudy start. If not fully vaccinated, participants must receive appropriateprophylactic antibiotic treatment until at least 2 weeks after the initial dose ofvaccine(s)

Exclusion Criteria:

• Participant has known positive serology for muscle-specific kinase

• Participant has any medical or psychiatric condition that, in the opinion of theInvestigator, could jeopardize or would compromise the participant's ability toparticipate in this study

• Participant has had a thymectomy within 6 months prior to Baseline

• Participant has minimal Manifestation Status of MG based on the clinical judgementof the Investigator

• Current or recent systemic infection within 2 weeks prior to Baseline or infectionrequiring intravenous antibiotics within 4 weeks prior to Baseline